These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10448610)

  • 21. Angiotensin-converting enzyme inhibitors and diuretics: optimal combination therapy.
    Krantz MJ; Mehler PS
    Ann Intern Med; 2004 Dec; 141(11):893; author reply 893. PubMed ID: 15583243
    [No Abstract]   [Full Text] [Related]  

  • 22. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study.
    Blacher J; Evans A; Arveiler D; Amouyel P; Ferrières J; Bingham A; Yarnell J; Haas B; Montaye M; Ruidavets JB; Ducimetière P;
    J Hypertens; 2004 Feb; 22(2):415-23. PubMed ID: 15076202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors].
    Scholze J; Unger T
    Internist (Berl); 2003 Sep; 44(9):1193-5. PubMed ID: 14566471
    [No Abstract]   [Full Text] [Related]  

  • 24. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.
    Psaty BM; Smith NL; Siscovick DS; Koepsell TD; Weiss NS; Heckbert SR; Lemaitre RN; Wagner EH; Furberg CD
    JAMA; 1997 Mar; 277(9):739-45. PubMed ID: 9042847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjunctive therapy after reperfusion therapy in acute myocardial infarction.
    Dries DL; Solomon AJ; Gersh BJ
    Clin Cardiol; 1998 Jun; 21(6):379-86. PubMed ID: 9631265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary and secondary prevention using lipid-lowering therapies.
    Holm K
    J Cardiovasc Nurs; 2000 Jan; 14(2):1-8. PubMed ID: 10653271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations.
    Fitchett DH; Goodman SG; Leiter LA; Lin P; Welsh R; Stone J; Grégoire J; Mcfarlane P; Langer A
    Can J Cardiol; 2016 Jul; 32(7 Suppl):S15-34. PubMed ID: 27342696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of lipids in primary and secondary prevention of cardiovascular diseases.
    Lavie CJ; Gau GT; Squires RW; Kottke BA
    Mayo Clin Proc; 1988 Jun; 63(6):605-21. PubMed ID: 3287024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Secondary prevention of ischemic heart disease: pharmacological treatment after myocardial infarction according to follow-up protocol].
    Milvidaite I; Luksiene D; Slapikiene B; Babarskiene MR; Liukaitis V; Maciulaitis R; Kadusevicius E; Pilviniene R
    Medicina (Kaunas); 2007; 43(2):131-6. PubMed ID: 17329948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in the treatment and secondary prevention of CHD at population level.
    Kattainen A; Salomaa V; Jula A; Antero Kesäniemi Y; Kukkonen-Harjula K; Kähönen M; Majahalme S; Moilanen L; Nieminen MS; Aromaa A; Reunanen A
    Scand Cardiovasc J; 2005 Dec; 39(6):327-33. PubMed ID: 16352484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacotherapy in the prevention of ischemic heart disease].
    Metelitsa VI
    Kardiologiia; 1987 Jan; 27(1):5-10. PubMed ID: 2882045
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacotherapy following myocardial infarction--a review of current treatment practices.
    Ørn S; Dickstein K
    Expert Opin Pharmacother; 2000 Sep; 1(6):1105-16. PubMed ID: 11249482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
    Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C
    Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
    Casella G; Greco C; Maggioni AP; Di Pasquale G
    G Ital Cardiol (Rome); 2006 Mar; 7(3):176-85. PubMed ID: 16572983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pathogenesis, diagnosis and conservative treatment of ischemic heart disease in patients with chronic renal failure].
    Imiela J
    Pol Arch Med Wewn; 2000 Oct; 104(4):671-9. PubMed ID: 11392155
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardioprotective potential of antihypertensives.
    Hansson L
    Am J Hypertens; 1995 Oct; 8(10 Pt 2):49S-52S. PubMed ID: 8845083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current therapies for secondary prevention after myocardial infarction.
    Cannon CE; Smith SC
    Curr Opin Cardiol; 1999 Mar; 14(2):155-60. PubMed ID: 10191975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of acute coronary syndromes.
    Schulman SP; Fessler HE
    Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacologic prevention of coronary artery disease. What do clinical trials show?
    Milani RV; Lavie CJ
    Postgrad Med; 1996 Feb; 99(2):109-12, 115-20. PubMed ID: 8632961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants.
    Kendall MJ; Rajman I; Maxwell SR
    Postgrad Med J; 1994 May; 70(823):329-43. PubMed ID: 8016003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.